Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design

Published:2022-01-27 Issue:3 Volume:17 Page:247-257
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Haider Kashif¹,Sharma Anku¹,Yar M Shahar¹²^ORCID,Yakkala Prasanna Anjaneyulu¹,Shafi Syed³,Kamal Ahmed¹⁴^ORCID

Affiliation:

1. Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

2. Centre for Excellence for Biomaterials Engineering, Faculty of Applied Sciences, Aimst University, Bedong, Malaysia

3. Department of Chemistry, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi, India

4. Department of Pharmacy, Birla Institute of Technology & Science, Pilani, Hyderabad Campus, India

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2022.2029842

Reference83 articles.

1. ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK

2. Phosphatidylinositol-3-OH kinase direct target of Ras

3. p21ras is modified by a farnesyl isoprenoid.

4. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins

5. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oxindoline Containing Thiazolidine‐4‐one Tethered Triazoles Act as Antimitotic Agents by Targeting Microtubule Dynamics;ChemistrySelect;2024-04-26

2. An update on the development on tubulin inhibitors for the treatment of solid tumors;Expert Opinion on Therapeutic Targets;2024-03-03

3. Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery;European Journal of Medicinal Chemistry;2024-03

4. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRASG12D-driven lung adenocarcinoma;Nature Communications;2023-09-20

5. RAS degraders: The new frontier for RAS-driven cancers;Molecular Therapy;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3